A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up

Anna Paczkowska,1 Karolina Hoffmann,2 Micha&lstrok; Michalak,3 Wies&lstrok;aw Bryl,2 Dorota Kopciuch,1 Tomasz Zaprutko,1 Piotr Ratajczak,1 El&zdot;bieta Nowakowska,4 Krzysztof Kus1 1Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Pozna&nacu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paczkowska A, Hoffmann K, Michalak M, Bryl W, Kopciuch D, Zaprutko T, Ratajczak P, Nowakowska E, Kus K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	type 2 diabetes non-adherence metformin insulin effectiveness of the treatment. Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/1661c9c61ca542c9a23e94019a495e83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1661c9c61ca542c9a23e94019a495e83
record_format	dspace
spelling	oai:doaj.org-article:1661c9c61ca542c9a23e94019a495e832021-12-02T16:12:38ZA Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up1178-7007https://doaj.org/article/1661c9c61ca542c9a23e94019a495e832021-07-01T00:00:00Zhttps://www.dovepress.com/a-comparison-between-the-therapeutic-effect-of-metformin-alone-versus--peer-reviewed-fulltext-article-DMSOhttps://doaj.org/toc/1178-7007Anna Paczkowska,1 Karolina Hoffmann,2 Micha&lstrok; Michalak,3 Wies&lstrok;aw Bryl,2 Dorota Kopciuch,1 Tomasz Zaprutko,1 Piotr Ratajczak,1 El&zdot;bieta Nowakowska,4 Krzysztof Kus1 1Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 2Department of Internal Diseases, Metabolic Disorders and Arterial Hypertension, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 3Department of Computer Science and Statistics, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 4Department of Pharmacology and Toxicology, Institute of Health Sciences, Collegium Medicum, University of Zielona Gora, Zielona Góra, PolandCorrespondence: Anna PaczkowskaDepartment of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 7 Street, Pozna&nacute;, 60-806, PolandTel +48 507 975 635Fax +48 618 546 894Email aniapaczkowska@ump.edu.plPurpose: The study aimed to compare the metabolic effects of an intensive dose of metformin alone among non-adherence patients with type 2 diabetes versus in combination with insulin among adherence patients.Methods: The prospective cohort study was carried out on a sample of 140 patients above 18 years old, divided into two groups. The first group (n=70) was recommended metformin monotherapy in an intensive dose of 2– 3 g/day, whereas the second group (n=70) was prescribed metformin (1– 2g/day) in combination with insulin. FPG, HbA1c, BMI, blood pressure, TC, TG, HDL-C, LDL-C, creatinine, and eGFR were measured for each patient at baseline and after a follow-up of 6 months of active treatment.Results: After six months of active treatment using monotherapy with an intensive dose of metformin, only 11.43% of patients achieved the target levels of HBA1c below 7%. In the group of patients treated using a combination of metformin with insulin, after six months of active treatment, 45.72% achieved HBA1c levels below 7% (p< 0.0001). Compared with an intensive dose of metformin alone, the combination of insulin and metformin was associated with improved glycemic control (change of fasting blood glucose: 2.49 mmol/l vs 1.30 mmol/l, p=0.0016). Metformin use alone, as compared with insulin, was associated with a significant increase in HDL-C (+0.03 mmol/l vs − 0.14 mmol/l, p=0.0485). Increased baseline obesity and increased baseline glycemia were the factors related to the likelihood of failing to achieve the target levels for HbA1c.Conclusion: Metformin proved to be more effective in controlling hyperglycemia when combined with insulin therapy. Our study shows how many health benefits loss patients who, despite systematic diabetes education, do not agree to change their treatment in the form of adding a second drug, including insulin.Keywords: type 2 diabetes, non-adherence, metformin, insulin, effectiveness of the treatmentPaczkowska AHoffmann KMichalak MBryl WKopciuch DZaprutko TRatajczak PNowakowska EKus KDove Medical Pressarticletype 2 diabetesnon-adherencemetformininsulineffectiveness of the treatment.Specialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 3243-3252 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes non-adherence metformin insulin effectiveness of the treatment. Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes non-adherence metformin insulin effectiveness of the treatment. Specialties of internal medicine RC581-951 Paczkowska A Hoffmann K Michalak M Bryl W Kopciuch D Zaprutko T Ratajczak P Nowakowska E Kus K A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up
description	Anna Paczkowska,1 Karolina Hoffmann,2 Micha&lstrok; Michalak,3 Wies&lstrok;aw Bryl,2 Dorota Kopciuch,1 Tomasz Zaprutko,1 Piotr Ratajczak,1 El&zdot;bieta Nowakowska,4 Krzysztof Kus1 1Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 2Department of Internal Diseases, Metabolic Disorders and Arterial Hypertension, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 3Department of Computer Science and Statistics, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 4Department of Pharmacology and Toxicology, Institute of Health Sciences, Collegium Medicum, University of Zielona Gora, Zielona Góra, PolandCorrespondence: Anna PaczkowskaDepartment of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 7 Street, Pozna&nacute;, 60-806, PolandTel +48 507 975 635Fax +48 618 546 894Email aniapaczkowska@ump.edu.plPurpose: The study aimed to compare the metabolic effects of an intensive dose of metformin alone among non-adherence patients with type 2 diabetes versus in combination with insulin among adherence patients.Methods: The prospective cohort study was carried out on a sample of 140 patients above 18 years old, divided into two groups. The first group (n=70) was recommended metformin monotherapy in an intensive dose of 2– 3 g/day, whereas the second group (n=70) was prescribed metformin (1– 2g/day) in combination with insulin. FPG, HbA1c, BMI, blood pressure, TC, TG, HDL-C, LDL-C, creatinine, and eGFR were measured for each patient at baseline and after a follow-up of 6 months of active treatment.Results: After six months of active treatment using monotherapy with an intensive dose of metformin, only 11.43% of patients achieved the target levels of HBA1c below 7%. In the group of patients treated using a combination of metformin with insulin, after six months of active treatment, 45.72% achieved HBA1c levels below 7% (p< 0.0001). Compared with an intensive dose of metformin alone, the combination of insulin and metformin was associated with improved glycemic control (change of fasting blood glucose: 2.49 mmol/l vs 1.30 mmol/l, p=0.0016). Metformin use alone, as compared with insulin, was associated with a significant increase in HDL-C (+0.03 mmol/l vs − 0.14 mmol/l, p=0.0485). Increased baseline obesity and increased baseline glycemia were the factors related to the likelihood of failing to achieve the target levels for HbA1c.Conclusion: Metformin proved to be more effective in controlling hyperglycemia when combined with insulin therapy. Our study shows how many health benefits loss patients who, despite systematic diabetes education, do not agree to change their treatment in the form of adding a second drug, including insulin.Keywords: type 2 diabetes, non-adherence, metformin, insulin, effectiveness of the treatment
format	article
author	Paczkowska A Hoffmann K Michalak M Bryl W Kopciuch D Zaprutko T Ratajczak P Nowakowska E Kus K
author_facet	Paczkowska A Hoffmann K Michalak M Bryl W Kopciuch D Zaprutko T Ratajczak P Nowakowska E Kus K
author_sort	Paczkowska A
title	A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up
title_short	A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up
title_full	A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up
title_fullStr	A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up
title_full_unstemmed	A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up
title_sort	comparison between the therapeutic effect of metformin alone versus a combination therapy with insulin in uncontrolled, non-adherence patients with type 2 diabetes: six months follow-up
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/1661c9c61ca542c9a23e94019a495e83
work_keys_str_mv	AT paczkowskaa acomparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT hoffmannk acomparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT michalakm acomparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT brylw acomparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT kopciuchd acomparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT zaprutkot acomparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT ratajczakp acomparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT nowakowskae acomparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT kusk acomparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT paczkowskaa comparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT hoffmannk comparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT michalakm comparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT brylw comparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT kopciuchd comparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT zaprutkot comparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT ratajczakp comparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT nowakowskae comparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup AT kusk comparisonbetweenthetherapeuticeffectofmetforminaloneversusacombinationtherapywithinsulininuncontrollednonadherencepatientswithtype2diabetessixmonthsfollowup
_version_	1718384336104849408

A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up

Ejemplares similares